Administration of anti-PD-L1 antibodies to CAFs-rich tumors suppresses tumor growth and activates tumor immunity, therefore, PD-L1-expressing CAFs are promising as a beneficial predictor of outcomes in patients with esophageal cancer. Here, CD274 is linked to esophageal cancer.